Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Corcept Therapeutics (CORT) Shares Outstanding (Diluted Average): 2016-2024

Historic Shares Outstanding (Diluted Average) for Corcept Therapeutics (CORT) over the last 9 years, with Dec 2024 value amounting to $113.5 million.

  • Corcept Therapeutics' Shares Outstanding (Diluted Average) rose 5.50% to $120.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $120.0 million, marking a year-over-year increase of 5.50%. This contributed to the annual value of $113.5 million for FY2024, which is 1.56% up from last year.
  • Per Corcept Therapeutics' latest filing, its Shares Outstanding (Diluted Average) stood at $113.5 million for FY2024, which was up 1.56% from $111.7 million recorded in FY2023.
  • In the past 5 years, Corcept Therapeutics' Shares Outstanding (Diluted Average) registered a high of $126.0 million during FY2021, and its lowest value of $111.7 million during FY2023.
  • For the 3-year period, Corcept Therapeutics' Shares Outstanding (Diluted Average) averaged around $113.7 million, with its median value being $113.5 million (2024).
  • Per our database at Business Quant, Corcept Therapeutics' Shares Outstanding (Diluted Average) declined by 7.94% in 2022 and then increased by 1.56% in 2024.
  • Corcept Therapeutics' Shares Outstanding (Diluted Average) (Yearly) stood at $124.2 million in 2020, then rose by 1.42% to $126.0 million in 2021, then declined by 7.94% to $116.0 million in 2022, then declined by 3.64% to $111.7 million in 2023, then increased by 1.56% to $113.5 million in 2024.